Appili Therapeutics Inc.
Appili Therapeutics Inc. (APLI.TO) Revenue
Annual & quarterly revenue history · segment & region breakdown
APLI.TO · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsAppili Therapeutics Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 87.86% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2017 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-03-31 | $0.00B | -$0.00B | -87.86% |
| 2024-03-31 | $0.00B | +$0.00B | +147.60% |
| 2023-03-31 | $0.00B | -$0.00B | -75.97% |
| 2022-03-31 | $0.00B | +$0.00B | — |
| 2021-03-31 | $0.00B | -$0.00B | -100.00% |
| 2020-03-31 | $0.00B | +$0.00B | — |
| 2019-03-31 | $0.00B | +$0.00B | — |
| 2018-03-31 | $0.00B | +$0.00B | — |
| 2017-03-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Appili Therapeutics Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Appili Therapeutics Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in CAD.
Data sourced from Appili Therapeutics Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
APLI.TO revenue · 4 questionsAPLI.TO's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 87.86% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Appili Therapeutics Inc. SEC filings · GAAP · Appili Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026